FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

Saved in:
Bibliographic Details
Published inOncotarget Vol. 6; no. 30; pp. 29782 - 29794
Main Authors Jones, Dominic, Wade, Mark, Nakjang, Sirintra, Chaytor, Lewis, Grey, James, Robson, Craig N., Gaughan, Luke
Format Journal Article
LanguageEnglish
Published 06.10.2015
Online AccessGet full text
ISSN1949-2553
1949-2553
DOI10.18632/oncotarget.4927

Cover

Author Gaughan, Luke
Jones, Dominic
Wade, Mark
Chaytor, Lewis
Robson, Craig N.
Grey, James
Nakjang, Sirintra
Author_xml – sequence: 1
  givenname: Dominic
  surname: Jones
  fullname: Jones, Dominic
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 2
  givenname: Mark
  surname: Wade
  fullname: Wade, Mark
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 3
  givenname: Sirintra
  surname: Nakjang
  fullname: Nakjang, Sirintra
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 4
  givenname: Lewis
  surname: Chaytor
  fullname: Chaytor, Lewis
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 5
  givenname: James
  surname: Grey
  fullname: Grey, James
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 6
  givenname: Craig N.
  surname: Robson
  fullname: Robson, Craig N.
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
– sequence: 7
  givenname: Luke
  surname: Gaughan
  fullname: Gaughan, Luke
  organization: Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
BookMark eNp1kE1LAzEQhoNUsNbePeYPbM0m2ezusRSrQqEXBW_LbDJbItukJLHQf2-qgiI4lxlm5pmP95pMnHdIyG3JFmWjBL_zTvsEYYdpIVteX5Bp2cq24FUlJr_iKzKP8Y1lq2Td8HZK-vX2dVnSgLv3ERJGCs4Ev0OXUxoPyQd6hGDBJQo62aNNJ2od3XuDY6R-oBpiCpksAkYb07nxEHwOEuaa0xhuyOUAY8T5t5-Rl_X98-qx2GwfnlbLTaG5UnVhKtmWnBvsh5b1FYBA0RjeIwMpWi1rgwgaajY0SipdKdP0wkCllREN10zMCPuaq_P-GHDoDsHuIZy6knWfMnU_MnVnmTKi_iDa5sutd_knO_4PfgBVGXW-
CitedBy_id crossref_primary_10_1002_pros_23497
crossref_primary_10_1158_1541_7786_MCR_23_0958
crossref_primary_10_18632_oncotarget_26239
crossref_primary_10_1007_s11523_016_0461_6
crossref_primary_10_18632_oncotarget_24515
crossref_primary_10_1016_j_theriogenology_2024_08_010
crossref_primary_10_3390_cancers14184441
crossref_primary_10_1038_srep40957
crossref_primary_10_3390_ijms22136676
crossref_primary_10_1158_1541_7786_MCR_18_1231
crossref_primary_10_3390_medicines6030082
crossref_primary_10_1016_j_euf_2019_04_020
crossref_primary_10_1089_adt_2021_128
crossref_primary_10_3390_ijms18102079
crossref_primary_10_1016_j_pharmthera_2017_08_003
crossref_primary_10_1158_1535_7163_MCT_18_1322
crossref_primary_10_1530_EO_22_0065
crossref_primary_10_1038_s41598_022_09371_x
crossref_primary_10_18632_oncotarget_22883
crossref_primary_10_32948_auo_2024_10_13
crossref_primary_10_1002_1878_0261_12770
crossref_primary_10_1242_dev_112672
crossref_primary_10_1242_jcs_207761
crossref_primary_10_18632_oncotarget_11902
crossref_primary_10_1007_s12094_016_1564_3
crossref_primary_10_3390_ijms19103279
crossref_primary_10_1093_nar_gkz286
crossref_primary_10_1016_j_celrep_2019_02_036
crossref_primary_10_1186_s13148_021_01023_7
crossref_primary_10_1016_j_mce_2017_08_002
crossref_primary_10_1093_nar_gkx1306
Cites_doi 10.1158/1078-0432.CCR-13-3296
10.1126/science.1168175
10.1530/ERC-13-0470
10.1007/s00345-011-0797-6
10.1158/2159-8290.CD-13-0226
10.1038/onc.2013.284
10.1093/nar/gkt469
10.1530/ERC-11-0141
10.1196/annals.1336.009
10.1074/jbc.M000660200
10.1158/0008-5472.CAN-08-0594
10.2174/1389450111314040005
10.1016/j.coph.2008.07.005
10.1056/NEJMoa1209096
10.1056/NEJMoa1014618
10.1056/NEJMoa1315815
10.1371/journal.pone.0027970
10.1038/ng.730
10.1007/s10555-013-9474-0
10.1158/0008-5472.CAN-12-3630
10.1158/0008-5472.CAN-12-2350
10.1172/JCI66398
10.1038/emboj.2011.328
10.1158/0008-5472.CAN-10-1998
10.1093/nar/gku1298
10.1038/onc.2011.637
10.1007/s10555-013-9473-1
10.1016/j.juro.2014.08.043
10.1038/onc.2013.508
10.18632/oncotarget.2924
10.7150/ijbs.8389
10.1158/0008-5472.CAN-11-3892
10.1158/2159-8290.CD-13-0142
10.1038/ncomms4972
10.1093/nar/gkq861
10.1056/NEJMoa1207506
10.1158/0008-5472.CAN-12-3468
10.1016/j.ccr.2011.09.001
10.1016/j.molcel.2007.05.041
10.2174/138920209787581307
10.1073/pnas.1421415111
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.18632/oncotarget.4927
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
EISSN 1949-2553
EndPage 29794
ExternalDocumentID 10_18632_oncotarget_4927
GroupedDBID ---
53G
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
FRJ
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
ID FETCH-LOGICAL-c2667-d549122debf90b5aa3e38d2be0a439c47deeaca70f8646c56d8b3da5c6d382c03
IEDL.DBID M48
ISSN 1949-2553
IngestDate Thu Apr 24 22:49:57 EDT 2025
Tue Jul 01 01:26:41 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 30
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2667-d549122debf90b5aa3e38d2be0a439c47deeaca70f8646c56d8b3da5c6d382c03
OpenAccessLink https://www.oncotarget.com/article/4927/pdf/
PageCount 13
ParticipantIDs crossref_primary_10_18632_oncotarget_4927
crossref_citationtrail_10_18632_oncotarget_4927
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-10-06
PublicationDateYYYYMMDD 2015-10-06
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-06
  day: 06
PublicationDecade 2010
PublicationTitle Oncotarget
PublicationYear 2015
References Tindall (24) 2008; 68
Isaacs (20) 2014; 67
Yu (19) 2014; 5
Dehm (28) 2012; 31
Carroll (18) 2014; 33
Huang (14) 2014; 10
Dehm (22) 2013; 14
Robson (44) 2013; 41
Carroll (15) 2012; 3
Brown (17) 2007; 27
Matusik (37) 2005; 1061
Hainsworth (4) 2012; 367
Luo (34) 2012; 72
Yu (41) 2013; 73
Paller (8) 2014; 371
Gaughan (45) 2015; 43
Schrijvers (6) 2013; 368
de Bono (3) 2014; 33
Pestell (13) 2000; 275
Sadar (39) 2013; 123
Hung (30) 2009; 324
Balk (32) 2011; 20
de Bono (1) 2014; 11
Janne (16) 2011; 30
Dehm (25) 2013; 73
Dong (33) 2014; 33
Dehm (27) 2014; 21
Scher (2) 2008; 8
Hager (36) 2013; 3
Dehm (40) 2015; 6
de Bono (5) 2014
Tindall (23) 2011; 18
Dehm (26) 2011; 71
Plymate (29) 2011; 6
Janne (31) 2013; 73
Tindall (35) 2015; 193
Robson (12) 2011; 39
Gao (38) 2014; 20
Santer (10) 2014; 33
Bevan (21) 2009; 10
Cheng (7) 2011; 364
Carroll (42) 2011; 43
Santer (11) 2012; 30
Zhu (9) 2013; 3
Minami (43) 2014; 111
References_xml – volume: 20
  start-page: 3198
  year: 2014
  ident: 38
  article-title: Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-3296
– volume: 324
  start-page: 787
  year: 2009
  ident: 30
  article-title: Development of a second-generation antiandrogen for treatment of advanced prostate cancer
  publication-title: Science
  doi: 10.1126/science.1168175
– volume: 21
  start-page: T87
  year: 2014
  ident: 27
  article-title: Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-13-0470
– volume: 30
  start-page: 297
  year: 2012
  ident: 11
  article-title: Androgen receptor co-activators in the regulation of cellular events in prostate cancer
  publication-title: World Journal of Urology
  doi: 10.1007/s00345-011-0797-6
– volume: 3
  start-page: 1020
  year: 2013
  ident: 36
  article-title: A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
  publication-title: Cancer Discovery
  doi: 10.1158/2159-8290.CD-13-0226
– volume: 33
  start-page: 3140
  year: 2014
  ident: 33
  article-title: Mechanisms of the androgen receptor splicing in prostate cancer cells
  publication-title: Oncogene
  doi: 10.1038/onc.2013.284
– volume: 41
  start-page: 6892
  year: 2013
  ident: 44
  article-title: KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt469
– volume: 18
  start-page: R183
  year: 2011
  ident: 23
  article-title: Alternatively spliced androgen receptor variants
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-11-0141
– volume: 1061
  start-page: 77
  year: 2005
  ident: 37
  article-title: Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially
  publication-title: Ann N Y Acad Sci
  doi: 10.1196/annals.1336.009
– volume: 275
  start-page: 20853
  year: 2000
  ident: 13
  article-title: p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M000660200
– volume: 68
  start-page: 5469
  year: 2008
  ident: 24
  article-title: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-0594
– volume: 14
  start-page: 441
  year: 2013
  ident: 22
  article-title: Androgen receptor gene rearrangements: new perspectives on prostate cancer progression
  publication-title: Curr Drug Targets
  doi: 10.2174/1389450111314040005
– volume: 8
  start-page: 440
  year: 2008
  ident: 2
  article-title: Targeting the androgen receptor pathway in prostate cancer
  publication-title: Current Opinion in Pharmacology
  doi: 10.1016/j.coph.2008.07.005
– volume: 368
  start-page: 138
  year: 2013
  ident: 6
  article-title: Abiraterone in metastatic prostate cancer without previous chemotherapy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209096
– volume: 364
  start-page: 1995
  year: 2011
  ident: 7
  article-title: Abiraterone and increased survival in metastatic prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1014618
– volume: 371
  start-page: 1028
  year: 2014
  ident: 8
  article-title: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1315815
– volume: 3
  start-page: 68
  year: 2012
  ident: 15
  article-title: FoxA1 is a key mediator of hormonal response in breast and prostate cancer
  publication-title: Frontiers in Endocrinology
– volume: 6
  start-page: e27970
  year: 2011
  ident: 29
  article-title: Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0027970
– volume: 43
  start-page: 27
  year: 2011
  ident: 42
  article-title: FOXA1 is a key determinant of estrogen receptor function and endocrine response
  publication-title: Nat Genet
  doi: 10.1038/ng.730
– volume: 33
  start-page: 413
  year: 2014
  ident: 10
  article-title: Androgen receptor signaling in prostate cancer
  publication-title: Cancer Metastasis Reviews
  doi: 10.1007/s10555-013-9474-0
– volume: 73
  start-page: 483
  year: 2013
  ident: 25
  article-title: Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-3630
– volume: 73
  start-page: 1570
  year: 2013
  ident: 31
  article-title: FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-2350
– volume: 123
  start-page: 2948
  year: 2013
  ident: 39
  article-title: An androgen receptor N-terminal domain antagonist for treating prostate cancer
  publication-title: J Clin Invest
  doi: 10.1172/JCI66398
– volume: 30
  start-page: 3962
  year: 2011
  ident: 16
  article-title: Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
  publication-title: EMBO J
  doi: 10.1038/emboj.2011.328
– volume: 71
  start-page: 2108
  year: 2011
  ident: 26
  article-title: Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1998
– volume: 43
  start-page: 196
  year: 2015
  ident: 45
  article-title: The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku1298
– volume: 31
  start-page: 4759
  year: 2012
  ident: 28
  article-title: AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
  publication-title: Oncogene
  doi: 10.1038/onc.2011.637
– volume: 33
  start-page: 555
  year: 2014
  ident: 3
  article-title: Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
  publication-title: Cancer Metastasis Reviews
  doi: 10.1007/s10555-013-9473-1
– volume: 193
  start-page: 690
  year: 2015
  ident: 35
  article-title: The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells
  publication-title: J Urol
  doi: 10.1016/j.juro.2014.08.043
– volume: 33
  start-page: 5666
  year: 2014
  ident: 18
  article-title: Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
  publication-title: Oncogene
  doi: 10.1038/onc.2013.508
– volume: 6
  start-page: 3811
  year: 2015
  ident: 40
  article-title: EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2924
– volume: 10
  start-page: 614
  year: 2014
  ident: 14
  article-title: Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer
  publication-title: International Journal of Biological Sciences
  doi: 10.7150/ijbs.8389
– volume: 11
  start-page: 365
  year: 2014
  ident: 1
  article-title: Evolution of androgen receptor targeted therapy for advanced prostate cancer
  publication-title: Nature Reviews
– year: 2014
  ident: 5
  article-title: Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
  publication-title: Eur Urol
– volume: 72
  start-page: 3457
  year: 2012
  ident: 34
  article-title: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-3892
– volume: 3
  start-page: 1030
  year: 2013
  ident: 9
  article-title: An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV100 (enzalutamide)
  publication-title: Cancer discovery
  doi: 10.1158/2159-8290.CD-13-0142
– volume: 5
  start-page: 3972
  year: 2014
  ident: 19
  article-title: Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program
  publication-title: Nature Communications
  doi: 10.1038/ncomms4972
– volume: 39
  start-page: 1266
  year: 2011
  ident: 12
  article-title: Regulation of the androgen receptor by SET9-mediated methylation
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkq861
– volume: 367
  start-page: 1187
  year: 2012
  ident: 4
  article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1207506
– volume: 73
  start-page: 3725
  year: 2013
  ident: 41
  article-title: Androgen receptor-independent function of FoxA1 in prostate cancer metastasis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-3468
– volume: 20
  start-page: 457
  year: 2011
  ident: 32
  article-title: Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.09.001
– volume: 67
  start-page: 470
  year: 2014
  ident: 20
  article-title: Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
  publication-title: Eur Urol
– volume: 27
  start-page: 380
  year: 2007
  ident: 17
  article-title: A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2007.05.041
– volume: 10
  start-page: 18
  year: 2009
  ident: 21
  article-title: The role of androgen receptor mutations in prostate cancer progression
  publication-title: Current Genomics
  doi: 10.2174/138920209787581307
– volume: 111
  start-page: 18261
  year: 2014
  ident: 43
  article-title: GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1421415111
SSID ssj0000547829
Score 2.1989772
SourceID crossref
SourceType Enrichment Source
Index Database
StartPage 29782
Title FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV09T8MwELVoWVgQCBDlo_LAwpDWiR07GRCqEKVCAhYqZYv8FQmpSktaEPx77pJAGcrA6jgZ7uzcO93de4RcaBeZkKsi4MxggqJ8kPqkCIQWWIWLHDM44PzwKCdTcZ_F2Xo8ujXgcmNqh3pS02o2-Hj9vIYLf4UXPpE8Gs6Rx6BunB6INFIdsl1Xi7CRrwX7DdO3gHCY1mVmkQaApXlbt9z0kV9x6lfAGe-R3RYp0lHj2n2y5csDYsZP2SikVaMg75dUI-EAHAJYwgaVeUXfIfsFc1GcWEBhCPpS0lrvZknnBbW6Jsr1AaTZCB1h4wIHP2AJnsEJqA7JdHz7fDMJWpmEwEJ0VYGDFC-MIudNkTITa809T8AFnmlAG1Yo5-HvqhUrEimkjaVLDHc6ttLxJLKMH5FuOS_9MaGOg4twcjC2WhgPUEBryQqhhEtiZ1WPDL-NktuWQxylLGY55hJoxnxtxhzN2COXP28sGv6MP_ee_GPvKdkB6FKTqDJ5Rrqr6s2fAzxYmT7p3GVhv_b9F1Kiv_g
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FOXA1+regulates+androgen+receptor+variant+activity+in+models+of+castrate-resistant+prostate+cancer&rft.jtitle=Oncotarget&rft.au=Jones%2C+Dominic&rft.au=Wade%2C+Mark&rft.au=Nakjang%2C+Sirintra&rft.au=Chaytor%2C+Lewis&rft.date=2015-10-06&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=6&rft.issue=30&rft.spage=29782&rft.epage=29794&rft_id=info:doi/10.18632%2Foncotarget.4927&rft.externalDBID=n%2Fa&rft.externalDocID=10_18632_oncotarget_4927
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon